-
公开(公告)号:US20240252499A1
公开(公告)日:2024-08-01
申请号:US18423217
申请日:2024-01-25
IPC分类号: A61K31/5375 , A61K9/00 , A61K31/192 , A61P13/12 , A61P17/04
CPC分类号: A61K31/5375 , A61K9/0014 , A61K9/0053 , A61K31/192 , A61P13/12 , A61P17/04
摘要: Treatment of uremic pruritus by administration of seladelpar or a salt thereof, or by administration of mavodelpar or a salt thereof.
-
公开(公告)号:US11596614B2
公开(公告)日:2023-03-07
申请号:US17221784
申请日:2021-04-03
发明人: Pol Boudes , Charles A. McWherter
IPC分类号: A61K31/192 , A61K9/00
摘要: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
-
公开(公告)号:US20210283078A1
公开(公告)日:2021-09-16
申请号:US17128195
申请日:2020-12-21
IPC分类号: A61K31/192 , A61P1/16 , A61K9/00
摘要: Treatment of cholestatic pruritus by therapy with seladelpar or a salt thereof.
-
公开(公告)号:US20210023031A1
公开(公告)日:2021-01-28
申请号:US17062545
申请日:2020-10-03
发明人: Pol Boudes , Charles A. McWherter
IPC分类号: A61K31/192 , A61K31/09
摘要: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
-
公开(公告)号:US20210000774A1
公开(公告)日:2021-01-07
申请号:US17024971
申请日:2020-09-18
发明人: Pol Boudes , Charles A. McWherter
IPC分类号: A61K31/192 , A61K9/00
摘要: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
-
公开(公告)号:US20200061006A1
公开(公告)日:2020-02-27
申请号:US16597313
申请日:2019-10-09
发明人: Pol Boudes , Charles A. McWherter
IPC分类号: A61K31/192 , A61K9/00
摘要: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
-
公开(公告)号:US10342770B2
公开(公告)日:2019-07-09
申请号:US16222379
申请日:2018-12-17
发明人: Brian Roberts , Xueyan Wang , Yun-Jung Choi , David Karpf , Robert Martin , Charles McWherter
IPC分类号: A61K31/192 , A61K31/33 , A61K9/00
摘要: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
-
公开(公告)号:US20190192459A1
公开(公告)日:2019-06-27
申请号:US16222325
申请日:2018-12-17
发明人: Pol Boudes , Charles A. McWherter
IPC分类号: A61K31/192 , A61K31/09
摘要: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
-
公开(公告)号:US20150290154A1
公开(公告)日:2015-10-15
申请号:US14684100
申请日:2015-04-10
发明人: Brian Roberts , Xueyan Wang , Yun-Jung Choi , David Karpf , Robert Martin , Charles McWherter
IPC分类号: A61K31/192
CPC分类号: A61K31/192 , A61K9/0053 , A61K31/33
摘要: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
摘要翻译: 用MBX-8025或MBX-8025盐治疗NAFLD和NASH。
-
10.Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and a Second Urate-Lowering Agent 有权
标题翻译: 使用卤代酸或卤代酸治疗痛风患者的高尿酸血症的方法和第二尿酸降解剂公开(公告)号:US20150258053A1
公开(公告)日:2015-09-17
申请号:US14667145
申请日:2015-03-24
IPC分类号: A61K31/216 , A61K31/426
CPC分类号: A61K31/426 , A61K9/0095 , A61K9/10 , A61K9/20 , A61K9/48 , A61K31/192 , A61K31/216 , A61K31/222 , A61K31/519 , A61K45/06 , A61K2300/00
摘要: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
摘要翻译: 本文公开了用于降低受试者的血清尿酸水平和用于治疗与升高的血清尿酸水平相关的病症的药物组合物,方法和试剂盒,其包括施用包含第一次尿酸盐降低剂和第二次降低尿酸的组合物 代理商 在一些方面,第一种降低尿酸的药剂是( - ) - 氟酸盐,( - ) - 卤味酸或其药学上可接受的盐。 在一些方面,第二种尿酸降低剂是尿酸生产的抑制剂,尿酸排泄剂,尿酸酶或其药学上可接受的盐。
-
-
-
-
-
-
-
-
-